Little now stands between us and untreatable gonorrhea.
In the US, for instance, the prevalence of ceftriaxone-resistant strains never went above 0.2 percent between 2017 and 2021.
[
add
]
[
|
|
...
]
Little now stands between us and untreatable gonorrhea.
In the US, for instance, the prevalence of ceftriaxone-resistant strains never went above 0.2 percent between 2017 and 2021.